Metaclipse Therapeutics Corporation

Metaclipse Therapeutics Corporation is a preclinical stage biotech company founded in 2010. The company's slogan, "Delivering breakthrough technologies to treat cancer and infectious disease," reflects its mission to develop novel cancer therapies tailored to each patient and their specific tumor. Its first 'personalized' cancer therapy targets triple negative metastatic breast cancer. The company intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing their safety and effectiveness in early clinical trials by year-end 2019. In July 2016, Metaclipse Therapeutics received a $2.40 million grant investment from the National Institutes of Health. This strategic investment underscores the potential of Metaclipse's innovative approach to cancer treatment and signifies recognition from an influential player in the field. As the company progresses towards bringing its personalized cancer therapy to the market, such investments further validate its potential impact on the biotechnology industry and, more importantly, on the lives of cancer patients. Overall, Metaclipse Therapeutics Corporation presents an exciting opportunity in the biotechnology sector, aiming to revolutionize cancer treatment and make significant strides in the fight against this disease. With promising developments in its pipeline and support from notable institutions, Metaclipse is positioned to make a substantial impact in the field of personalized medicine and oncology.